Her primary areas of study are Virology, Virus, Drug resistance, Genetics and Phylogenetics. Her work on Lentivirus as part of her general Virology study is frequently connected to Human T-lymphotropic virus, thereby bridging the divide between different branches of science. In her research, Glycan is intimately related to Mutation, which falls under the overarching field of Virus.
Her work carried out in the field of Drug resistance brings together such families of science as Regimen, Viral load, Didanosine, Combination therapy and Drug. Her study in Phylogenetics is interdisciplinary in nature, drawing from both Evolutionary biology, Molecular epidemiology and Phylogenetic tree. Her biological study deals with issues like Genetic variation, which deal with fields such as Genotype.
Kristel Van Laethem mostly deals with Virology, Drug resistance, Genetics, Virus and Genotype. Her Virology research includes elements of Molecular biology, Reverse transcriptase and Immunology. She has researched Immunology in several fields, including Acquired immunodeficiency syndrome and Cohort.
Kristel Van Laethem has included themes like Bioinformatics, Regimen, Internal medicine, Genotyping and Drug in her Drug resistance study. Her research investigates the connection with Virus and areas like Glycosylation which intersect with concerns in Mannose. Her research in Genotype focuses on subjects like Integrase inhibitor, which are connected to Integrase.
Kristel Van Laethem focuses on Drug resistance, Virology, Genotype, Internal medicine and Genetics. Kristel Van Laethem interconnects Reverse transcriptase, Bioinformatics, Regimen, Computational biology and Drug in the investigation of issues within Drug resistance. Kristel Van Laethem combines subjects such as Protein structure, Concordance and Acquired immunodeficiency syndrome with her study of Virology.
Her work deals with themes such as Integrase inhibitor, Amino acid, Antibody and HIV Protease Inhibitor, which intersect with Genotype. Her studies deal with areas such as Transmission, Viral load and Antiretroviral therapy as well as Internal medicine. As part of the same scientific family, Kristel Van Laethem usually focuses on Genetics, concentrating on Evolutionary biology and intersecting with NS5A and Protease inhibitor.
The scientist’s investigation covers issues in Drug resistance, Genotype, Genetics, Immunology and Transmission. Her Drug resistance study integrates concerns from other disciplines, such as Regimen, Internal medicine and Drug. Her Genetics study combines topics in areas such as Evolutionary biology and Genetic diversity.
Her study looks at the relationship between Evolutionary biology and topics such as Virus, which overlap with Genotyping. The subject of her Viral load research is within the realm of Virology. Her Virology study combines topics from a wide range of disciplines, such as Pcr assay and Antiretroviral therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management
Annemarie M. J. Wensing;David A. van de Vijver;Gioacchino Angarano;Birgitta Åsjö.
The Journal of Infectious Diseases (2005)
Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis
Joris Hemelaar;Ramyiadarsini Elangovan;Jason Yun;Leslie Dickson-Tetteh.
Lancet Infectious Diseases (2019)
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
Kristel Van Laethem;Andrea De Luca;Andrea Antinori;Antonello Cingolani.
Antiviral Therapy (2002)
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
Dimitrios Paraskevis;Dimitrios Paraskevis;Oliver Pybus;Gkikas Magiorkinis;Angelos Hatzakis.
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
L. Marije Hofstra;Nicolas Sauvageot;Jan Albert;Jan Albert;Ivailo Alexiev.
Clinical Infectious Diseases (2016)
Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120 A NEW THERAPEUTIC CONCEPT TO HIT THE ACHILLES HEEL OF HIV
Jan Balzarini;Kristel Van Laethem;Sigrid Hatse;Matheus Froeyen.
Journal of Biological Chemistry (2005)
Managing resistance to anti-HIV drugs: an important consideration for effective disease management.
Anne-Mieke Vandamme;Kristel Van Laethem;Erik De Clercq.
Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes
Jan Balzarini;Kristel Van Laethem;Willy J. Peumans;Els J. M. Van Damme.
Journal of Virology (2006)
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
David A van de Vijver;Annemarie M J Wensing;Gioacchino Angarano;Birgitta Asjö.
Journal of Acquired Immune Deficiency Syndromes (2006)
Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus
Jan Balzarini;Kristel Van Laethem;Dirk Daelemans;Sigrid Hatse.
Journal of Virology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: